Prof Evangelos Terpos speaks to ecancer at EHA 2024 about his EAE116 study.

The EAE116 study is a phase 2 clinical trial investigating the effects of isatuximab, bortezomib, cyclophosphamide, and dexamethasone (Isa-VCd) as induction therapy in newly diagnosed multiple myeloma patients with severe renal impairment.

Preliminary results from 43 patients show that Isa-VCd induces significant hematologic and renal responses, with a renal response rate of 60.5% and an overall response rate of 82.9%.

The safety profile is consistent with known data, with no new safety concerns.

Further follow-up is needed for a comprehensive evaluation of long-term outcomes.